Avero Diagnostics

What Avero Diagnostics does

Avero Diagnostics is a CLIA-certified, CAP-accredited anatomic pathology and molecular diagnostics laboratory operating as the laboratory services arm of Northwest Pathology, P.S. (PLLC), headquartered in Bellingham, Washington, with national specimen reach across the United States and international distribution. The company delivers six core subspecialty pathology service lines — gynecologic, molecular, gastrointestinal, urologic, dermatopathology, and breast pathology — supported by 10 board-certified, fellowship-trained pathologists and a test menu of approximately 30+ specialized diagnostic panels spanning infectious disease, women's health, urology, and oncology (including NAAT/RT-PCR, FISH, IHC with quantitative scoring, and liquid-based cytology workflows).

Provider-facing infrastructure includes Avero Connect (EMR/LIS integration for automated result delivery), Avero Link (Pathology Portal for online results access), and a Provider Portal built on the LigoLab platform; the proprietary AveroSwab specimen collection kit anchors the supply chain, and the AveroCares program offers need-based financial assistance.

The company operates on a fee-for-service billing model, charging per specimen using standard CPT codes (e.g., 88300–88309 for histopathology) with billing routed to insurers, Medicare, or patients; pricing varies with specimen complexity, and self-pay prompt-payment discounts are offered. Go-to-market is enterprise field sales targeting clinics, healthcare systems, hospitals, and public health departments, with no consumer-direct channel and no disclosed external venture or private equity backing.

Name

Avero Diagnostics

Legal name

Northwest Pathology, P.S.

Website

https://averodx.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Avero Diagnostics is a CLIA-certified, CAP-accredited anatomic and molecular pathology laboratory serving US healthcare providers with subspecialty pathology services, a 30+ panel molecular test menu, and integrated EMR/LIS ordering and results delivery.

Ownership category

akta.pro rank

Product category

Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Point-of-Care Testing (POCT) & Near-Patient Labs (HLAFAMAI)

Keywords

• Anatomic pathology services
• Molecular diagnostic testing
• Clinical laboratory services
• Women's health diagnostics
• Subspecialty pathology testing

Headquarters

HQ city

Irving

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Laboratory Diagnostic Services: Fee-for-service laboratory testing model where healthcare providers submit specimens for pathology and molecular diagnostic testing. Services are billed to insurance providers, Medicare, or patients directly based on coverage determination. Most tests are performed at Avero facilities with specimens potentially sent to reference laboratories for specialized tests not performed in-house.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Avero Diagnostics operates a CLIA-certified, CAP-accredited anatomic and molecular pathology laboratory in Bellingham, Washington, providing diagnostic testing services across six subspecialty service lines (gynecologic, molecular, gastrointestinal, urologic, dermatopathology, and breast). The company delivers diagnostic results to healthcare providers nationwide through direct specimen submission, EMR/LIS integration (Avero Connect), and an online provider portal (Avero Link), with billing to insurance providers, Medicare, or patients based on coverage.

Product overview

Avero Diagnostics operates as a CLIA-certified and CAP-accredited anatomic pathology and molecular diagnostics laboratory. The company's portfolio consists of six core pathology service lines (Gynecologic, Molecular, Gastrointestinal, Urologic, Dermatopathology, and Breast Pathology) supported by a comprehensive test menu of approximately 30+ specialized diagnostic panels. Core reporting infrastructure includes Avero Connect (EMR/LIS integration), Avero Link (online portal access), a Provider Portal (built on LigoLab platform), and a Payment Portal. Patient-facing offerings include the AveroCares financial assistance program. The services are delivered primarily from the Bellingham, WA laboratory, with reference testing capabilities for specialized tests not performed in-house.

Differentiator

Problem solved

Functional benefit

Brands

• Avero Connect: Electronic medical record (EMR) or laboratory information system (LIS) integration for report delivery.
• Avero Link
• AveroCares
• AveroSwab

Products and services

• Gynecologic Pathology Women's health pathology services including Pap tests, FISH testing, and molecular diagnostics for conditions affecting the female reproductive system; for healthcare providers.
• Molecular Pathology Molecular diagnostics using nucleic acid amplification and PCR technologies for infectious disease detection and cancer diagnostics; for healthcare providers.
• Gastrointestinal Pathology Fellowship-trained GI pathology services providing diagnostic reports for gastroenterology practices; for gastroenterologists and healthcare providers.
• Urologic Pathology Urologic pathology services for prostate, bladder, and renal pathology with molecular testing including FISH and PCR; for urologists and healthcare providers.
• Dermatopathology Board-certified dermatopathologist services for accurate skin disease and melanoma diagnostics; for dermatologists and healthcare providers.
• Breast Pathology Breast cancer diagnostics focused on early detection and therapy selection through prognostic marker testing; for breast surgeons, oncologists, and healthcare providers.
• Genital Ulcer Panel Molecular panel detecting HSV 1 and 2, Haemophilus ducreyi (chancroid), and Treponema pallidum (syphilis) using NAAT methodology; 24-48 hour turnaround time.
• Leukorrhea Extended Panel Molecular panel detecting Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium.
• Leukorrhea Panel Molecular panel detecting Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
• AMBLor Test Dermatopathology test for melanoma involving immunostaining of the epidermis using 4μm tissue sections on charged slides.
• Histopathology/Tissue Specimens Routine histopathology services using formalin-fixed tissue and frozen section diagnostics.
• COVID-19 Molecular Test RT-PCR testing for SARS-CoV-2 using Thermo Fisher or Hologic platforms with multiple specimen types including nasal, NP, and OP swabs.
• Gynecologic Pap Test (ThinPrep) Liquid-based cytology preparation using ThinPrep methodology with image-guided screening; 2-5 day turnaround.
• Dtex Cervical FISH Fluorescent in-situ hybridization (FISH) testing for cervical specimen analysis.
• Group B Strep with Broth Enrichment RT-PCR detection of Group B Streptococcus using LIM broth enrichment methodology.
• Breast Prognostic Panel Immunohistochemistry panel testing ER, PgR, Her2, Ki67, and p53 antibodies for breast cancer prognosis; 72-hour turnaround.
• Urine Cytology Microscopic evaluation of urine specimens for urologic cancer detection; 72-hour turnaround.
• UroVysion FISH Fluorescence in-situ hybridization test for bladder cancer detection using urine specimens.
• Chlamydia/Gonorrhoeae NAAT panel detecting Chlamydia trachomatis and Neisseria gonorrhoeae.
• High-Risk HPV/HPV Genotyping HPV genotyping panel detecting strains 16, 18, 31, 45, 33/58, 35/39/68, 51, 52, and 56/59/66 with mRNA NAAT methodology.
• Herpes Simplex Virus 1 & 2 Molecular detection of HSV 1 and HSV 2 using NAAT.
• Bacterial Vaginosis Panel Molecular panel detecting Gardnerella vaginalis, Atopobium vaginae, Megasphaera spp., BVAB2, Mobiluncus species, and Lactobacillus species.
• Candidiasis Panel Molecular panel detecting Candida albicans, C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei.
• Cervicitis/Vaginitis Panel Comprehensive panel detecting CT/NG, TV, Candidiasis, BV, MP, and UP pathogens.
• PID/Infertility Panel Panel detecting CT/NG, TV, BV, MP, and UP for pelvic inflammatory disease and infertility workup.
• Averoswab Standard Panel Molecular panel detecting vaginal microbiota including Lactobacillus species, Gardnerella vaginalis, and Candida species using proprietary AveroSwab collection kit.
• Trichomonas vaginalis Molecular detection of Trichomonas vaginalis.
• Vaginosis/Vaginitis Panel Panel detecting Trichomonas vaginalis, Bacterial Vaginosis, and Candidiasis.
• Aerobic Vaginitis Panel Panel detecting Escherichia coli, Enterococcus faecalis, Group B Streptococcus, and Staphylococcus aureus.
• Mycoplasma Panel Molecular panel detecting Mycoplasma genitalium and Mycoplasma hominis.
• UTI Complete Panel Comprehensive urine pathogen panel detecting over 30 organisms including bacteria, Candida species, and Ureaplasma using RT-PCR.
• Vaginosis/Vaginitis Extended Panel Extended panel detecting CT/NG, TV, BV, and Candidiasis.
• Anal Pap Test and HPV Screening Anal cytology and HPV screening using liquid-based preparation and nucleic acid amplification.
• AveroCares Financial Assistance Program Need-based financial assistance program for patients based on household income levels according to US Department of Health & Human Services poverty guidelines.

Quantifiable outcome

• 24-48 hour turnaround time for Genital Ulcer Panel testing
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• ADx HealthminorOthersLinked as a partner resource on Avero Diagnostics website footer, providing health-related information and services.
• Versant NorthwestminorOthersReferenced in footer as a partner organization (VersantDx/Versant Northwest) related to Avero Diagnostics laboratory operations.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Inform Diagnostics: Specialty anatomic and molecular pathology provider focused on dermatopathology, GI, GU, and breast — directly overlapping Avero's core subspecialty mix and serving a similar community-provider referral base.

Broad incumbents

• Quest Diagnostics: Largest US clinical reference laboratory with a national specimen-receiving network and a broad menu that includes molecular diagnostics and women's health. Direct overlap with Avero's routine and specialty test categories, but at vastly greater scale.
• Sonic Healthcare: Global reference lab operator with US anatomic pathology presence (including via the Aurora Diagnostics acquisition) offering multi-subspecialty pathology and molecular diagnostics — a larger-scale competitor in the same specialty pathology space.
• Laboratory Corporation of America (LabCorp): Major national reference lab offering overlapping women's health, molecular, and anatomic pathology services. Competes with Avero for routine specimen referrals and employer/provider outreach contracts at much greater scale.

Others

• LigoLab: Laboratory information system provider whose platform powers Avero's Provider Portal and Payment Portal. Included as the technology backbone peer rather than a clinical competitor.
• Versant Diagnostics: Listed as an affiliate/parent-organization partner of Avero via Northwest Pathology, P.S. Comparable regional pathology network with multi-subspecialty focus; included for ecosystem context rather than head-to-head competition.

Direct peers

• ProPath: Independent specialty pathology practice offering multi-subspecialty anatomic pathology and molecular diagnostics with national reach. Closely comparable operational model and provider-referral motion to Avero.
• PathGroup: Large independent pathology practice with multi-subspecialty anatomic pathology and molecular diagnostics, serving community providers across multiple states — the closest operational and go-to-market analogue to Avero.
• NeoGenomics: Specialty oncology and molecular diagnostics lab with strong anatomic pathology subspecialty coverage and a women's health focus (especially hereditary cancer). Direct specialty competitor to Avero in molecular and cancer diagnostics.
• Myriad Genetics: Specialty molecular diagnostics company with focus on hereditary cancer, women's health (BRACAnalysis), and oncology companion diagnostics — partial overlap with Avero on breast/gynecologic molecular testing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/averodx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avero Diagnostics